Key points are not available for this paper at this time.
The results suggest that an accurate measurement of receptor density and flow before therapy could be a promising approach for developing an individualized treatment with 177 Lu-labeled PSMA-targeting radioligands.
Hardiansyah et al. (Fri,) studied this question.